Edwards Lifesciences (EW)

• Market cap: $45B
• 1 day: 1.66%
• 5 days: 1.75%
• 1 month: 9.85%
• 3 months: 0.74%
• 6 months: 16.01%
• Year to date: 5.73%
• 1 year: -11.23%
• 5 years: 5.89%
• 10 years: 252.71%
• Sector: Healthcare
• Industry: Medical Devices

About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Employees: 15,800

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

122% more call options, than puts

Call options by funds: $586M | Put options by funds: $264M

67% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]

30% more first-time investments, than exits

New positions opened: 184 | Existing positions closed: 141

19% more capital invested

Capital invested by funds: $31.4B [Q3] → $37.5B (+$6.11B) [Q4]

6.28% more ownership

Funds ownership: 78.78% [Q3] → 85.06% (+6.28%) [Q4]

2% more funds holding

Funds holding: 1,180 [Q3] → 1,204 (+24) [Q4]

30% less repeat investments, than reductions

Existing positions increased: 347 | Existing positions reduced: 496

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $75 2% downside
• Avg. target: $77 0% upside
• High target: $83 8% upside

4 analyst ratings

• positive: 1 25%
• neutral: 3 75%
• negative: 0 0%

Piper Sandler Adam Maeder 64% 1-year accuracy 9 / 14 met price target	8% upside $83	Overweight Maintained	13 May 2025
Canaccord Genuity William Plovanic 43% 1-year accuracy 20 / 47 met price target	2% downside $75	Hold Maintained	25 Apr 2025
Baird David Rescott 59% 1-year accuracy 10 / 17 met price target	2% downside $75	Neutral Maintained	24 Apr 2025
Truist Securities Richard Newitter 56% 1-year accuracy 28 / 50 met price target	2% downside $75	Hold Maintained	11 Apr 2025